A Study to See How Well Lebrikizumab Works in Adults and Adolescents With Moderate Atopic Dermatitis (Eczema) and High Itch Burden
Phase 4
200
about 1.3 years
12+
35 sites in AL, AZ, CA +13
What this study is about
Researchers are testing how well lebrikizumab works for adults and adolescents with moderate atopic dermatitis, a condition causing itchy skin. The trial will last up to 38 weeks, including 6 months of treatment.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Lebrikizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
lebrikizumab
Primary: Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) (≥75% Reduction from Baseline in EASI), or a ≥4-point Reduction in Pruritus Numerical Rating Scale (NRS) from Baseline
Secondary: Change from Baseline in Body Surface Area (BSA) Involvement, Change from Baseline in Children's Dermatology Quality of Life (CDLQI), Change from Baseline in Dermatology Quality of Life (DLQI), Percentage Change from Baseline in Sleep-loss Scale, Percentage of Change from Baseline in Pruritus NRS Score, Percentage of Participants Achieving a ≥4-point Reduction from Baseline in Pruritus NRS, Percentage of Participants with a Skin Pain NRS of ≥4 Points at Baseline Who Achieve a ≥4-point Reduction
Dermatology